Peptide record

TPDB92079

V13K Antibacterial Anticancer Antifungal Antiparasitic Hemolysis Toxicity modified_plain modified
26 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.

Standard-residue backbone model; source-recorded chemical modifications are not verified in these coordinates.

TPDB92079
V13K
Antibacterial Anticancer Antifungal Antiparasitic Hemolysis Toxicity
Anti-infective peptides Cancer-related peptides Toxicity and safety peptides
AntiBP3 dbAMP DRAMP Peptipedia ACP740 _ACP240 AntiCP 2.0 CancerPPD 2.0 SATPdb dbACP iACP-DRLF Antifungipept CAFPdb HemoPI Hemolytic2 PD_Hemolysis
modified_plain
Yes
A 26-aa modified multi-activity (Antibacterial, Anticancer, Antifungal, and other sources) peptide sequence curated from AntiBP3, dbAMP, DRAMP, and other sources, with an available 3D structural model.
C-terminal: Amidation N-terminal: Acetylation
Sequence
Ac-KWKSFLKTFKSAKKTVLHTALKAISS-NH2
Physicochemical Analysis

Sequence-only estimates are not provided for modified or non-standard source notation. Reported molecular properties, when available, are retained below with their source records.

Chemical Descriptors
26 reviewed residue count
Amidation Activity
L Activity
Linear Activity
Acetylation Activity
Antimicrobial and Anticancer Activity
Synthetic Activity
Evidence Records 4 records
Evidence 1 Activity

Activity

IC50
IC50 = 16 ± 0.5 µM
Anticancer
16

Target

Cervical Cancer
HeLa
Cervix

Assay & Model

MTT assay
24-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2017

Other

Source Activity Label Source Definition
Anticancer
CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.
Evidence 2 Activity

Activity

IC50
IC50 = 24.8 ± 0.6 µM
Anticancer
24.8

Target

Pancreatic Cancer
MIA PaCa-2
Pancreas

Assay & Model

MTT assay
24-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2017
Evidence 3 Activity

Activity

IC50
IC50 = 7.6 ± 4.0 µM
Anticancer
7.6

Target

Pancreatic Cancer
HPAC
Pancreas

Assay & Model

MTT assay
24-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2017
Evidence 4 Activity

Activity

IC50
IC50 = 12.5 ± 1.2 µM
Anticancer
12.5

Target

Pancreatic Cancer
BxPC-3
Pancreas

Assay & Model

MTT assay
24-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2017